CLSI Grows Staff and Board
CLSI is pleased to announce the expansion of its Innovation Services division with the addition of Shikha Sharma, PhD, who serves as CLSI’s Director of Operations, and Johnson Yang, who is serving as CLSI’s new Program Manager. Both will support the Institute’s entrepreneurship, education, and partnership initiatives.
Shikha previously worked at Innovation Ventures (IV) at University of California, San Francisco for 8 years. In IV, she worked with scientists, clinicians, attorneys, investors, & multiple cross-functional teams to move university research towards commercial development. In her role as a Senior Officer of Licensing, Engagement & Opportunity Development at UCSF, she performed commercial valuation & intellectual property (IP) assessment of hundreds of new technologies in therapeutics, devices, diagnostics, software, and digital health. She has formulated patent & commercialization strategies for pioneering stem cell technologies, novel gene therapy technologies, CRISPR based platforms, next-gen neuromodulation devices, AI based technologies & data mining within the electronic health systems (EHR). She has negotiated multi-million-dollar venture deals, pharma alliances, start-up collaborations etc.
Prior to joining CLSI, Johnson served as a visiting CIRM fellow for two years at Stanford University, where he gained tremendous experience in stem cell translational research. Johnson completed his bachelor’s degree in Cellular and Molecular Biology at San Francisco State University. Most recently, Johnson received his Master’s degree in Biological Science with an emphasis on Stem Cells. Johnson hopes to apply his skills to help bridge the gap between business and biological life science.
CLSI has been honored to welcome some formidable individuals and women onto its board this year, including Monica Beam, Ph.D., SVP, Science & Technology at Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments, Mara Brazer, CEO of Brazer Communications, Lisa Carmel, VP Stratgey, Ximedica, and Gail Maderis, CEO of Antiva Biosciences.